Chemed Corporation

source: coverage-next-full | ticker: CHE | step: "01" | created: 2026-05-29

Step 01 — Business Overview: Chemed Corporation (CHE)

Company Summary

Chemed Corporation is a Cincinnati-based holding company that owns two operationally distinct but financially complementary businesses: VITAS Healthcare, the largest for-profit hospice provider in the United States, and Roto-Rooter, the nation's leading consumer plumbing and drain cleaning services brand. The combination is unusual — healthcare services and home services — but produces a powerful and diversified cash flow engine with defensive characteristics in both segments.

The Two-Segment Structure

VITAS Healthcare (~70% of Revenue)

VITAS Healthcare Corporation is the crown jewel of Chemed's portfolio. Founded in 1978 in Miami, Florida, VITAS was acquired by Chemed in 2004 and has since grown to become the largest for-profit hospice provider in the US by both revenue and average daily census (ADC). VITAS serves terminally ill patients with a prognosis of six months or less, providing palliative care in patients' homes, nursing facilities, assisted living facilities, and inpatient hospice units.

Key Characteristics:

• Serves approximately 18,000-20,000 patients per day (ADC)
• Operates in 14 states + Washington D.C. (primary footprint: Florida, Ohio, Texas, California, New Jersey, Georgia)
• Revenue is almost entirely Medicare and Medicaid reimbursed (~98%)
• Revenue model is per-diem: Medicare pays a daily rate per patient enrolled in hospice benefit
• Four levels of care: Routine Home Care (RHC, ~95% of patient days), Continuous Home Care, Inpatient Respite Care, General Inpatient Care (GIP)
• Medicare hospice benefit is federally mandated and updated annually via CMS rulemaking

Competitive Position:

• #1 for-profit hospice provider in the US (ahead of Amedisys/LHC, Encompass, and thousands of small regional operators)
• Scale advantages in nurse hiring, Medicare cost report management, and regulatory navigation
• Certificate of Need (CON) regulations in some states provide partial competitive barriers

Roto-Rooter (~30% of Revenue)

Roto-Rooter Group, Inc. traces its roots to 1935 and is one of America's most recognized home services brands. It provides plumbing repair and maintenance, drain cleaning, water restoration, and HVAC services across the US and Canada through a combination of company-owned branches and franchised operations.

Key Characteristics:

• Revenue from company-owned branches (majority) and franchise royalties
• Emergency plumbing services: ~55-60% of revenue (non-discretionary, 24/7/365 call response)
• Water/fire/smoke restoration and HVAC: ~40-45% of revenue
• Operates in all 50 states + Canada
• ~50,000+ service calls per week at peak

Competitive Position:

• #1 consumer plumbing brand by brand recognition and revenue
• Franchise network creates national coverage with capital-light economics
• 24/7 emergency response creates recurring, high-urgency demand

Why This Combination Works

The two businesses are complementary in several important ways:

1. Counter-cyclicality: VITAS is recession-resistant (hospice demand is demographic-driven), while Roto-Rooter is largely non-discretionary (plumbing emergencies don't pause in recessions). Both hold up well in downturns.

2. Cash flow diversity: VITAS generates predictable, government-reimbursed cash flows. Roto-Rooter generates market-rate consumer cash flows. Neither is correlated with the other.

3. Capital allocation flexibility: Roto-Rooter's higher EBITDA margins and lower reinvestment needs generate excess cash that funds VITAS capacity expansion and corporate buybacks/dividends.

4. Management bandwidth: Both businesses are operationally mature with dedicated management teams. Chemed corporate functions as a lean holding company.

Historical Context

Chemed was originally spun out of W.R. Grace & Co. in 1982. For decades it held diversified industrial/chemical businesses. The strategic transformation began with the Roto-Rooter acquisition in 1987 and culminated with the VITAS acquisition in 2004 for ~$406M — one of the best acquisitions in healthcare services history given VITAS's subsequent growth.

Investment Narrative

Chemed is a classic "quality compounder" story:

• Secular tailwind in hospice (aging US population, growing Medicare hospice utilization)
• Dominant #1 market positions in both segments
• Predictable, high-quality earnings with minimal capex requirements
• Management team with exceptional capital allocation record (buybacks, dividends, no dilutive M&A)
• Stock trades at a modest premium to the market but at a discount to pure-play healthcare services peers

Revenue Mix (Approximate FY2024)

Operating Structure

Chemed employs approximately 16,000-17,000 people across both segments (VITAS is the larger employer, primarily nurses, social workers, chaplains, and home health aides). Roto-Rooter employs technicians, dispatchers, and administrative staff.

Key Investor Considerations

• VITAS Medicare mix: Any changes to CMS hospice reimbursement rates directly impact ~70% of Chemed's revenue
• ADC trajectory: The single most important VITAS metric; COVID disrupted hospice referral patterns for 2+ years
• Roto-Rooter normalization: Post-COVID correction in plumbing demand is largely behind the company
• Litigation/settlement risk: VITAS settled a significant False Claims Act investigation in 2023; risk is always present in a Medicare-reimbursed business

source: coverage-next-full | ticker: CHE | step: "12" | created: 2026-05-29

Step 12 — Catalysts: Chemed Corporation (CHE)

Near-Term Catalysts (0-12 Months)

1. VITAS ADC Inflection Confirmation (Q1-Q2 2025)

The most important near-term catalyst is confirmation that VITAS's ADC growth has reached a new secular trend, not a cyclical bounce. Q4 2024 ADC of ~20,500 was an all-time high. If Q1 2025 (seasonally the strongest quarter) shows ADC of 21,000+, it would confirm that:

• Baby Boomer mortality wave is now a visible contributor to census growth
• Post-COVID ADC suppression is fully behind the company
• The DOJ settlement had created operational headwinds that have now fully cleared

A strong Q1 2025 ADC print would likely cause upward revisions to FY2025 and FY2026 estimates.

2. CMS FY2025 Final Hospice Rule

CMS typically issues the final hospice reimbursement rule in August, effective for the following fiscal year. The FY2025 rule (effective Oct 1, 2024) already set the rate at ~+2.9%. The FY2026 proposed rule (issued spring 2025) will set the next year's rate. A favorable rate update of 3%+ would:

• Provide direct revenue uplift for VITAS (~$50M revenue impact per 1% rate change at $1.7B base)
• Potentially trigger EPS estimate upgrades

3. Roto-Rooter Revenue Comps Ease (H2 2025)

Roto-Rooter's revenue comparison base becomes easier in H2 2025 (the company was already showing YoY declines in H2 2024). Any stabilization or return to growth in Roto-Rooter volumes would:

• Remove the modest negative sentiment around the segment
• Allow Roto-Rooter to contribute positively to consolidated revenue growth again

4. Accelerated Buyback Activity

With Net Debt/EBITDA at ~1.2x and FCF approaching $260-280M/year, management has significant capital allocation flexibility. An accelerated buyback (above the ~$215M FY2024 pace) or a buyback authorization increase would:

• Signal management confidence in the trajectory
• Accelerate EPS growth through faster share count reduction

Medium-Term Catalysts (1-3 Years)

5. VITAS Geographic Expansion

VITAS currently operates in 14 states + DC. The US has ~50 states and VITAS is absent or underrepresented in large markets such as:

• New York, Pennsylvania, Illinois, Michigan, North Carolina
• Each new program launch takes 12-24 months to reach breakeven, then compounds

New market launches would be a catalyst for re-rating the ADC growth multiple.

6. Medicare Advantage Hospice Carve-In

The GUIDE model (CMS's Guiding an Improved Dementia Experience pilot) and discussions around potentially moving hospice from traditional Medicare into Medicare Advantage are long-term policy debates. A managed care "carve-in" could:

• Alter per-diem reimbursement to a capitated model
• Potentially favor large operators (VITAS) over small ones in contract negotiations
• Create significant uncertainty in the near-term but structural opportunity for scale players

7. Roto-Rooter Housing Recovery

If the Federal Reserve's rate-cutting cycle accelerates housing market normalization (more home sales, more renovation activity), Roto-Rooter could see its non-emergency restoration segment recover. This could restore segment revenue growth to the 4-6% range.

8. Sum-of-Parts Recognition / Potential Spin-off

Chemed's conglomerate structure creates a persistent valuation discount vs. peers:

• VITAS would likely trade at 14-16x EBITDA as a standalone (in line with hospice M&A multiples)
• Roto-Rooter would likely trade at 12-14x EBITDA as a standalone
• The combined entity trades at ~17-18x EBITDA

If management ever pursued a separation of Roto-Rooter, it could unlock 10-20% value. Management has historically shown no interest in this, but it remains a latent catalyst.

Long-Term Catalysts (3-10 Years)

9. Baby Boomer Mortality Wave

The demographic tailwind is just beginning. The oldest Baby Boomers (born 1946) are 79 in 2025; the youngest (born 1964) are 61. Annual US deaths are projected to increase by ~30-40% by 2040. VITAS, as the largest hospice provider, is positioned to benefit disproportionately from this secular trend. This is the biggest long-term catalyst — simply the arithmetic of population aging.

10. Hospice Utilization Rate Expansion

~48% of Medicare decedents still do not use hospice. This is a massive untapped market. As physician attitudes evolve, as cultural acceptance of palliative care grows, and as family caregivers increasingly advocate for hospice, the utilization rate should continue rising from ~52% toward 65-70%.

Bull Case

• VITAS ADC accelerates to 8-10% annual growth through 2027 as Baby Boomer mortality wave intensifies and hospice utilization rate expands; CMS rates increase 3-4%/year; combined VITAS revenue grows 11-14% annually, driving EBIT margin expansion to 15%+ as operating leverage compounds
• Roto-Rooter returns to 3-5% annual revenue growth as housing market normalizes post-rate-cut cycle; operating margins hold above 25% through pricing discipline
• Management deploys $250M+/year in buybacks at 20-22x adjusted earnings; share count falls by 4-5%/year; adjusted EPS reaches $28-32 by FY2027

Bear Case

• CMS implements material hospice reimbursement cuts (e.g., restructuring GIP rates) or a new OIG investigation creates legal overhang, compressing VITAS operating margins to 8-9% and causing consensus estimate cuts of 15-20%
• Nursing labor shortage worsens materially, with wage inflation re-accelerating to 7-8% while CMS rate increases remain 2-3%; VITAS margin compression is sustained over 2-3 years
• Roto-Rooter faces digital platform competition that accelerates market share losses; revenues decline 3-5% for multiple years while technician wage inflation persists; segment EBIT falls below $150M